Kashiv is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $5.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Kashiv's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Xolair AVT23 |
Roche / Novartis | Biosimilar | 2026 | In development | ≈$5.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Kashiv's share of it.